Merck & Co., Inc.
MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30242% above fair value
$148.36−1.16 (-0.78%)
Close on Nov 2, 2026Market cap $366.03BP/E 118.7Yield 2.21%
Merck U.S. Depreciation Expense by Year
U.S. Depreciation Expense ($B)
Merck U.S. Depreciation Expense: $2.20B in FY2025, up 57.1% from a year earlier.
Latest, FY2025
2.20
Period ended Dec 31, 2025
Change on a year earlier
+57.1%
1.40 in FY2024
History
7 years
Since FY2019
Sources
5
Documents cited below
Where the FY2025 figure comes from
“Depreciation expense was $3.0 billion in 2025, $2.1 billion in 2024 and $1.8 billion in 2023, of which $2.2 billion in 2025, $1.4 billion in 2024 and $1.2 billion in 2023, related to locations in the U.S.”
Source: Form 10-K (mrk-20251231.htm, filed 2026-02-24) ↗
Reported in Form 10-K Segment Footnote.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | U.S. Depreciation Expense ($B) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 2.20 | +57.1% | Form 10-K (mrk-20251231.htm, filed 2026-02-24) ↗ |
| FY2024 | Dec 31, 2024 | 1.40 | +16.7% | Form 10-K (mrk-20251231.htm, filed 2026-02-24) ↗ |
| FY2023 | Dec 31, 2023 | 1.20 | -7.7% | Form 10-K (mrk-20251231.htm, filed 2026-02-24) ↗ |
| FY2022 | Dec 31, 2022 | 1.30 | +18.2% | Form 10-K (mrk-20241231.htm, filed 2025-02-25) ↗ |
| FY2021 | Dec 31, 2021 | 1.10 | -8.3% | Form 10-K (mrk-20231231.htm, filed 2024-02-26) ↗ |
| FY2020 | Dec 31, 2020 | 1.20 | 0.0% | Form 10-K (mrk-20221231.htm, filed 2023-02-24) ↗ |
| FY2019 | Dec 31, 2019 | 1.20 | – | Form 10-K (mrk-20211231.htm, filed 2022-02-25) ↗ |
Cite this data
StockData. (2026). Merck U.S. Depreciation Expense, annual FY2019–FY2025 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/depr-us-b
See every metric in the Merck KPI table. Data updated Oct 26, 2026.